Evocutis, the skincare products testing group, managed to double revenues in the year to July 31st.
Turnover from commercial deals jumped from £0.22m to £0.46m, helped by collaboration and consultancy agreements with consumer healthcare companies.
The large increase in revenue was mainly as a result of the full-year trading revenues from Leeds Skin Centre for Applied Research which was acquired in May 2011.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The adjusted operating loss narrowed to £0.91m, from £1.09m previously. The loss per share reduced from 0.90p to 0.88p.
"These results show that the integration of Syntopix and Leeds Skin into Evocutis has led to significant growth in collaborations with major multi-national companies. Our collaborators are seeking the skill base at the core of Evocutis that enables them to strengthen their brands by providing scientific data that supports product claims," said interim Chief Executive Officer Gwyn Humphreys.
"Evocutis aims to grow these relationships over the coming twelve months, and to increase the availability of LabSkin for those companies who wish to carry out research in-house rather than by contract relationships with Evocutis."
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
-
What does Rachel Reeves’s plan for growth mean for UK investors?Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
